; ;
Run your own event Donations as a gift Volunteer At work Corporate Partnerships
Participating Hospitals In development Recruiting In follow-up Completed Endorsed Studies Publications Funding
Aims & Objectives Our Board Advisory Committee Consumer Panel Membership Network International Partners Achievements Publications Funding
donate


login

PUBLICATIONS

2011 Manuscripts

  1. Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck DA, Whittom R, Langer C, O'Callaghan CJ. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology 2011; 22(1): 118–126. Published online 5 July 2010.
  2. Clarke S, Yip S, Brown C, van Hazel G, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ; on behalf of the Australasian Gastro-Intestinal Trials Group. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer. Published online 10 Jun 2011.
  3. Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, Gebski V, Miller D, Shannon J. Fixeddose- rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology 2011; 67(3): 519–525. Published online 12 May 2010.
  4. Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter, IWT, Hruby G, Horvath L, Bydder S, Undercill C, Harvey J, Gebski VJ; on behalf of the Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer. Published online 1 Dec 2011.
  5. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. Journal of Clinical Oncology 2011; 29(19): 2675–2682. Published online 6 Jun 2011.
  6. Price TJ, Zannino D, Wilson K, Simes J, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the agitg MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Annals of Oncology. Published online 29 Oct 2011.
  7. Sjoquist K, Burmeister B, Smithers BM, Zalcberg JR, Simes J, Barbour A, Gebski V; on behalf of the Australasian Gastro-Intestinal Trials Group(AGITG) Meta-analysis of survival after neoadjuvant chemotherapy or chemoradiotherapy followed by surgery for resectable oesophageal carcinoma: updated results. Lancet Oncology 2011; 12(7): 681–692. Published online 17 Jun 2011.

2011 Conference abstracts

  1. Elimova E, O Callaghan CJ, Tu D, Karapetis CS, Price TJ, Zhu L, Zalcberg JR, Simes J, Jonker DJ. Cetuximab related hypersensitivity reactions: An analysis of timing, demographics, and outcomes from the AGITG / NCIC CTG CO.17 trial. American Society of Clinical Oncology Annual Meeting; 4– 8 Jun 2011; Chicago.
  2. Neoptolemos JP, Mooore MJ, Cox TF, Valle JW, Palmer DH, McDonald A, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Coxon FY, Lacaine F, Middleton R, Ghaneh P, Bassi C, Halloran C, Olah A, Rawcliffe CL, Büchler MW, European Study Group for Pancreatic Cancer. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago. Journal of Clinical Oncology 2011; 29 (suppl.). Abstract LBA4006.
  3. O'Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Tebbutt NC, Trudeau MG, Price TJ, Yip D, Jonker DJ. The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.
  4. Paul J, Briggs A, Harkin A, Haydon AM, Iveson T, Masterson M, Midgley RA, Cassidy J. SCOT: Short Course Oncology Therapy—A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. Journal of Clinical Oncology 2011; 29 (suppl.). Abstract e14145.
  5. Price T, Zannino D, Wilson K, van Hazel G, Robinson B, Broad A, Ganju V, Ackland S, Simes J, Tebbutt N. Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine, bevacizumab, and mitomycin C; first-line metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium; 20–22 Jan 2011; San Francisco. Abstract 510.
  6. Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Outcome and dose intensity in the elderly subgroup of the AGITG MAX phase III trial of capecitabine, bevacizumab, and mitomycin C in first-line metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.
  7. Rao A, Sjoquist K, Goldstein D. Second and third line chemotherapy in advanced gastric or gastro-oesophageal cancer: a single institution retrospective case series and review of the literature. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Asia-Pacific Journal of Clinical Oncology 2011; 7(S4): 119. Abstract 211. AGITG publications 5-Dec-11 3
  8. Schofield PE, Stockler MR, Zannino D, Wong N, Ransom D, Moylan EJ, Simes RJ, Price TJ, Tebbutt NC, Jefford M; on behalf of the Australasian GastroIntestinal Trials Group. Do hope, optimism and other psychological factors predict survival in patients with metastatic colorectal cancer? IPOS 13th World Congress of Psycho-Oncology; 16–20 Oct 2011; Antalya, Turkey.
  9. Shapiro J, Siu LL, Zalcberg J, Moore M, Ringash J, Mittmann N, Simes J, O’Callaghan CJ, Tu D, Walters I, Magoski N, Smith P, Nomikos D, Zhu L, Savoie M, Virk S, El-Tahche F, Gill R, Price T, Jonker D. A phase III study of cetuximab plus either brivanib alaninate versus placebo in patients with chemotherapy-refractory KRAS wild-type advanced colorectal cancer. The NCIC CTG/AGITG CO.20 trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.
  10. Van Hazel GA, Tu D, Tebbutt C, Jonker DJ, Price TJ, O’Callaghan C, Zalcberg JR, Simes J, Yip D, Jefford M, Strickland AH, Burnell MJ, Karapetis CS. Early change in tumor size from waterfall plot analysis and RESIST response as predictor of overall survival in advanced, chemotherapy-refractory colorectal cancer: NCIC CTG/AGITG CO.17 study. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.
  11. Vickers MM, Karapetis C, Tu D, Zalcberg J, O’Callaghan C, Simes J, Moore M, Zhu L, Jonker DJ. The influence of hypomagnesemia on overall survival in a phase III randomized study of cetuximab plus best supportive care (BSC) versus BSC: NCIC CTG / AGITG CO.17. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.
  12. Weickhardt AJ, Williams D, Lee C, Simes J, Murone C, Wilson K, Cummins M, Asadi K, Price TJ, Mariadason J, Tebbutt NC; Australasian Gastro- Intestinal Trials Group. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer: analysis of the phase III MAX study. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

2010 Manuscripts

  1. Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, Gebski V, Miller D, Shannon J. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology. Published online 12 May 2010.

  2. Tebbutt NC, Cummins MM, Sourjina T, Strickland AH, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. andomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer  2010; 102: 475–481. Published online 12 Jan 2010.

  3. Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck DA, Whittom R, Langer C, O'Callaghan CJ. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology. Published online 5 July 2010.

  4. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua YJ, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab and mitomycin C in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomised phase III MAX study. Journal of Clinical Oncology 2010; 28(19): 3191–3198. Published online 1 June 2010.

  5. De Roock S, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of Kras p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304(16): 1812–1820.

  6. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler, MW; for the European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA.2010; 304(10): 1073–1081.

2010 Conference abstracts

  1. Desai J, Goldstein D, McArthur G, Hicks R, Fox S, Kotasek D, Kang YK, Bracken K, Gebski V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. The REGISTER study: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago.

  2. Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial:- an AGITG multicentre phase II study of fixed-dose-rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. Asian Oncology Summit; 9–11 Apr 2010; Nusa Dua, Bali.

  3. Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, Joseph DJ, McClure B, McLachlan SA, Mackay J. A randomized trial comparing local recurrence rates between short course and long course preoperative radiotherapy for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSA, RACS). American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago. Journal of Clinical Oncology 2010; 28 (7 suppl). Abstract 3509.

  4. Price TJ, Hardingham J, Lee C, Weickhardt A, Townsend A, Wrin JW, Shivasami A, Cummins M, Murone C, Tebbutt N. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab ± mitomycin C in advanced colorectal cancer. ESMO Congress; 8–12 Oct 2010; Milan.

  5. Schofield P, Stockler M, Zannino Z, Wong N, Ransom D, Moylan E, Simes RJ, Price TJ, Tebbutt NC, Jefford M; Australasian Gastrointestinal Trials Group (AGITG). Hope, optimism and survival in a randomized trial of first line chemotherapy for patients with metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago. Journal of Clinical Oncology 2010; 28 (7 suppl). Abstract 9039.

  6. Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Primrose JN, Walpole ET, Nordlinger B. Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago. Journal of Clinical Oncology 2010; 28 (7 suppl). Abstract 3544.

  7. Stockler M, Zannino D, Wilson K, Gebski V, Abdi A, Strickland A, Lowenthal RM, Simes RJ, Price TJ, Tebbutt NC; Australasian Gastro-Intestinal Trials Group (AGITG).Patient-rated outcomes in a randomized trial of first line chemotherapy with capecitabine, bevacizumab, and mitomycin-c for metastatic colorectal cancer: the AGITG MAX trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago. Journal of Clinical Oncology 2010; 28 (suppl). Abstract e14036.

2009 Manuscripts

  1. Au HJ, Karapetis CS, O’Callaghan CJ, Tu D, Moore MJ, Zalcberg J, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Health-related quality of life in advanced colorectal cancer patients treated with cetuximab: overall and Kras-specific results of the NCIC CTG and AGITG CO.17 trial. Journal of Clinical Oncology 2009; 27(11): 1822–1828. Published online 9 March 2009.

  2. Hicks S, James R, Wong N, Tebbutt NC, Wilson S. A case study comparison of ethical review systems for multicentre clinical trials in Australia. Medical Journal of Australia 2009; 191(5): 280–282.

  3. Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced gastrointestinal stromal tumors treated with imatinib mesylate: the Intergroup EORTC-ISG-AGITG phase III trial. Journal of Clinical Oncology 2009;27(24): 3969–3974. Published online 20 Jul 2009. [AGITG].

  4. Michael M, Price T, Ngan SY, Ganju V, Strickland AH, Muller A, Khamly K, Milner AD, Dilulio J, Matera A, Zalcberg JR, Leong T. A phase I trial of capecitabine + gemcitabine with radical radiation for locally advanced pancreatic cancer. British Journal of Cancer 2009; 100 (1): 37–43. Published online 16 Dec 2008.

  5. Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group–Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. Journal of the National Cancer Institute 2009: 101(17): 1182–1192. Published online 7 Aug 2009.

  6. Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. British Journal of Cancer 2009; 100(2): 246–250. Published online 6 Jan 2009.

2009 Conference abstracts

  1. Clarke SJ, Brown C, Simes J, Van Hazel G, Jeffery M, Tebbutt N, Ransom D, Buck M, Boland A, Zalcberg J; Australasian Gastro-Intestinal Trials Group. AGITG DaVINCI Trial: Randomised phase II trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan in patients with previously treated metastatic colorectal cancer. Gastrointestinal Cancers Symposium; 15–17 Jan 2009; San Francisco.

  2. Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial: an AGITG multicentre phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. Annual Meeting of the American Society of Clinical Oncology ; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4616.
  3.  Jonker D, Karapetis C, Harbison C, O’Callaghan C, Tu D, Simes J, Xu LA, Moore M, Zalcberg J, Khambata-ford S. High epiregulin gene expression plus KRAS wild-type status predict for cetuximab benefit in the treatment of advanced colorectal cancer: results from NCIC CTG CO.17: a phase III trial of cetuximab vs best supportive care. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando.
  4. Neoptolemos J, Büchler M, Stocken DD, Ghaneh P, Smith D, Bassi C, Moore M, Cunningham D, Dervenis C, Goldstein D. ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 18s. Abstract LBA4505. [AGITG]

  5. Powell ED, Asmis T, Jonker D, Tu C, Karapetis C, Jeffery m, O’Callaghan C. Comorbidity and overall survival in cetuximab-treated patients with advanced colorectal cancer—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4074. [AGITG]

  6. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay J-Y and Hogendoorn PCW, on behalf of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clinical Cancer Research 2009; 15: 4191–4198.

  7. Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomised phase III study of capecitabine, bevacizumab and mitomycin C in first line metastatic colorectal cancer: final results of the AGITG MAX trial. ECCO 15 and 34th ESMO Multidisciplinary Congress; 20–24 Sep 2009; Berlin.

  8. Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomised phase III study of capecitabine, bevacizumab, and mitomycin C in first-line treatment of metastatic colorectal cancer: final results of the AGITG MAX trial. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4023.

  9. Van Glabbeke MM, Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichardt P, Issels R, Judson I, Debiec-Rychter, Blay J. Type of progression in patients treated with imatinib for advanced gastrointestinal stromal tumor: a study based on the EORTC-ISG-AGITG trial 62005. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 10536. [AGITG]

2008 Manuscripts

  1. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 2008; 359(17): 1757–1765.

  2. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371(9617): 1007–1016. [AGITG]

  3. Nowak AK, Cebon J, Hargreaves C, Dhillon H, Findlay M, Gebski V, Stockler MR. Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology 2008; 4: 55-67.

  4. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Annals of Oncology 2008; 19(Suppl 6): vi1–vi8.

2008 Conference abstracts

  1. Australasian Gastrointestinal Trials Group; Shannon JA, Goldstein D, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Jones-Murphy M. A phase II trial of gemcitabine in fixed dose rate infusion combined with low dose cisplatin in patients with inoperable biliary tract carcinomas. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 243.

  2. Grimison PS, Tebbutt N, Price T, van Hazel G, Wilson K, Tunney V, Stockler M. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients’ perspectives using baseline data from the MAX study of the Australasian Gastro-Intestinal Trials Group (AGITG). Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 449.

  3. Karapetis C, Khambata-Ford S, Jonker D, O’Callaghan C, Tu D, Vachan B, Simes J, Langer C, Moore M, Zalcberg J. K-ras mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer — results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. 33rd Congress of the European Society of Medical Oncology; 12–16 Sep 2008; Stockholm. Annals of Oncology 2008; 19: viii2. Abstract LBA6.

  4. Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes J, Evans WK, Jonker DJ. A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 6528.

  5. Ngan SY, McLachlan SA, Fisher R, Burmeister B, Joseph D, Hruby G, Ackland S, Ganju V, Mackay J, Solomon M. A comparison of quality of life in patients with rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group, Australasian Gastrointestinal Trials Group, Colorectal Surgical Society of Australia and New Zealand, and Royal Australasian College of Surgeons trial. Royal Australian and New Zealand College of Radiologists 59th Annual Scientific Meeting; 16–19 Oct 2008; Adelaide.

  6. O’Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Zalcberg JR, Trudeau M, Yip D, Vachan B, Jonker DJ. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC–CTC CO.17. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 4130.

  7. Price T, Gebski V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K, Tunney V, Tebbutt N. International multicentre randomised phase II–III study of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer: final safety analysis of the AGITG MAX trial. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 4029.

  8. Price TJ, Gebski V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K, Tunney V, Tebbutt N. AGITG MAX trial—capecitabine, bevacizumab, and mitomycin C in metastatic colorectal cancer: safety analysis of 400 patients in an international multi-centre randomized phase II–III study. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 449.

  9. Price TJ, Gebski V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K , Tunney V, Tebbutt N. Safety analysis of an international multi-centre randomised phase II–III study of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer: AGITG MAX trial. 33rd Congress of the European Society for Medical Oncology; 12–16 Sep 2008; Stockholm. Annals of Oncology 2008; 19 (suppl. 8): viii127. Abstract 365P.

  10. Shannon JA, Goldstein D, Brown C, Tebbutt N, Ackland S, van Hazel G, Abdi E, Jefford M, Gainford MC, Jones-Murphy M. A phase II trial of gemcitabine in fixed dose rate infusion combined with low dose cisplatin in patients with inoperable biliary tract carcinomas. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando.

  11. Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, Gebski V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 87.

  12. Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, Gebski V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 15554.

  13. Wetzig N, Brown C, Gebski V, Gill P, Stockler M. Relationship between clinicians’ measurements of arm volume and patients’ ratings of arm-swelling in the RACS SNAC trial of sentinel node based management for early breast cancer. 6th Biennial International Sentinel Node Society Meeting; 18-20 Feb 2008; Sydney.

  14. Wilson K, Munro SC, James R, Tebbutt N, Price TJ, Shapiro J, Wong N. Comparison of ethical and regulatory processes in two multicentre, multiregional oncology clinical trials: an Australian perspective. Clinical Research Excellence 08; 7–9 Aug 2008; Brisbane.

2007 Manuscripts

  1. Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D; on behalf of the AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. Australian and New Zealand Journal of Surgery 2007; 77(4): 247–252.

  2. Gebski V, Burmeister B, Smithers MB, Foo K, Zalcberg J, Simes J. Meta-analysis of the survival benefits from preoperative chemoradiation therapy and chemotherapy in oesophageal carcinoma. Lancet Oncology 2007; 8: 226–234.

  3. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007; 357(20): 2040–2048.

  4. Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. Journal of Clinical Oncology 2007; 25(4): 424–430.

  5. Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 2007; 110(9): 1945–1950. [NSABP]

  6. Kuebler JP, Wieand S, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. Journal of Clinical Oncology 2007; 25(16): 2198–2204.

  7. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology 2007; 25(16): 2205–2211.

  8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007; 25(15): 1960–1966.

  9. Verweija J, Casalib PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, Issels R, van Oosterom AT, Van Glabbeke M, Blay JY. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. European Journal of Cancer 2007; 43(6): 974–978.

2007 Conference abstracts

  1. Au H, Karapetis C, Jonker D, O’Callaghan C, Kennecke H, Shapiro J, Tu D, Wierzbicki R, Zalcberg J, Moore M. Quality of life in patients with advanced colorectal cancer treated with cetuximab: results of the NCIC CTG and AGITG CO.17 trial. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 4002.

  2. Goldstein D, Shannon J, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Adams K; for the Australasian Gastro-Intestinal Trials Group. ABC: an AGITG trial of fixed dose rate gemcitabine and cisplatin for patients with advanced biliary tract cancer. 43rd Annual Scientific Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 15015.

  3. Grimison PS, Tebbutt N, Price T, van Hazel G, Wilson K, Tunney V, Stockler M. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients’ perspectives using baseline data from the MAX study of the Australasian Gastro-Intestinal Trials Group (AGITG). 35th Annual General Meeting of the Clinical Oncological Society of Australia; 14–17 Nov 2007; Adelaide.

  4. Gruenberger T, Sorbye H, Debois M, Bethe U, Primrose J, Rougier P, Jaeck D, Finch-Jones M, Van Cutsem E, Nordlinger B, EORTC GI group. Tumor response to preoperative chemotherapy with Folfox-4 for resectable colorectal cancer liver metastases. Interim results of EORTC Intergroup randomized phase III study 40983. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2006; 24 (18S, Part I): 3500.

  5. Jonker DJ, Karapetis CS Moore MJ, Zalcberg JR, Tu D, Au H, Berry S, Krahn M, Simes RJ, Tebbutt N, van Hazel G, O'Callaghan CJ. A phase III randomized study of cetuximab (Erbitux, C225) and best supportive care versus best supportive care in patients with pretreated metastatic colorectal carcinoma. Ameri
    can Association for Cancer Research Annual Meeting    ; 14–18 Apr 2007; Los Angeles.
  6. Julié C, Lutz MP, Aust D, Kandutsch S, Collette L, Praet M, Gruenberger T, Van Cutsem E, Nordlinger B. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. Gastrointestinal Cancers Symposium, 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago.

  7. Julié C, Lutz MP, Aust D, Kandutsch S, Collette L, Praet M, Gruenberger T, Van Cutsem E, Nordlinger B. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. Gastrointestinal Cancers Symposium, 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago.

  8. Nordlinger B, Sorbye H, Collette L, et al. Survival after peri-operative chemotherapy with Folfox 4 and surgery for resectable colorectal cancer liver metastases. Final results of the EORTC Intergroup randomized phase III study 40983. World Congress on Gastrointestinal Cancer; 28 Jun–1 Jul 2007; Barcelona. Annals of Oncology 2007;

  9. Tebbutt NC, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Gebski V, Munro S, Cummins M; on behalf of the Australasian GI Trials Group. ATTAX: randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5-FU or capecitabine in metastatic oesophago-gastric cancer: final results of an AGITG trial. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago.

  10. Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX study: MAXimising a clinical trial. 28th Annual Meeting of the Society for Clinical Trials; 20–23 May 2007; Montreal.

  11. Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX Study: MAXimising trial outcomes in a multi-centred, multi-regional clinical trial. International Clinical Trials Symposium; 24–26 Sep 2007; Sydney.

  12. Van Glabbeke MM. Owzar K, Rankin C, Simes J, Crowley J; GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1640 patients. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 10004.

2006 Manuscripts

  1. Cebon J, Hargreaves C, Stockler M, Nowak A, Dhillon H, Dickman B, Gebski V; Australasian Gastro-Intestinal Trials Group (AGITG) AG0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer 2006; 95(7): 853–861.

  2. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Gastro-Intestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer 2006; 42(8): 1093–103.

  3. Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral Uracil and Tegafur Plus Leucovorin Compared with Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of Clinical Oncology 2006; 24(13): 2059-64.

  4. Van Glabbeke M, Verweij J, Casali PG, Simes J, Cesne AL, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC- IS G-AGITG). European Journal of Cancer 2006; 42(14): 2277–2285.

2006 Conference abstracts

  1. Gruenberger T, Sorbye H, Debois M, Bethe U, Primrose J, Rougier P, Jaeck D, Finch-Jones M, Van Cutsem E, Nordlinger B, EORTC GI group. Tumor response to preoperative chemotherapy with Folfox-4 for resectable colorectal cancer liver metastases. Interim results of EORTC Intergroup randomized phase III study 40983. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2006; 24 (18S, Part I): 3500.

  2. Le Cesne A, Van Glabbeke M, Verweij J, Casali P, Zalcberg J, Reichardt P, Issels RD, Judson IR, Blay JY. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate included in the intergroup EORTC/ISG/AGITG trial? Journal of Clinical Oncology 2006; 24 (18S, Part 1): 9510

  3. Tebbutt N, Gebski V, Strickland A, Gibbs D, Walpole E, Ganju V, Goldstein D, Munro S, Harrod M, Van Hazel G, Australasian Gastro-Intestinal Trials Group. Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. 42nd Annual Meeting of the American Society of Clinical Oncology; 2–6 Jun 2006; Atlanta. Journal Of Clinical Oncology 2006; 24 (18): 194S. 4067.

  4. Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX study: MAXimising a clinical trial. Applied Clinical Trials 13th Annual European Summit; 17–19 Oct 2006; Amsterdam.

2005 Manuscripts

  1. Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. British Journal of Cancer 2005; 93: 1235–1243.

  2. Burmeister BH , Smithers BM , Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, for the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology 2005; 6(9): 659–668.

  3. GLe Cesne A, Van Glabbeke M, Verweij J, Casali P, Zalcberg J, Reichardt P, Issels RD, Judson IR, Blay JY. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate included in the intergroup EORTC/ISG/AGITG trial? Journal of Clinical Oncology 2006; 24 (18S, Part 1): 9510

  4. Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response—an AGITG study. Oncology 2005; 69(4): 326–332.

  5. Gruenberger T, Sorbye H, Debois M, Bethe U, Primrose J, Rougier P, Jaeck D, Finch-Jones M, Van Cutsem E, Nordlinger B, EORTC GI group. Tumor response to preoperative chemotherapy with Folfox-4 for resectable colorectal cancer liver metastases. Interim results of EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology 2006; 24 (18S, Part I). Abstract 3500. [AGITG]

  6. Tebbutt N, Gebski V, Strickland A, Gibbs D, Walpole E, Ganju V, Goldstein D, Munro S, Harrod M, Van Hazel G, Australasian Gastro-Intestinal Trials Group. Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. 42nd Annual Meeting of the American Society of Clinical Oncology; 2–6 Jun 2006; Atlanta. Journal Of Clinical Oncology 2006; 24 (18): 194S. 4067.

  7. Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX study: MAXimising a clinical trial. Applied Clinical Trials 13th Annual European Summit; 17–19 Oct 2006; Amsterdam.

  8. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PCW, Brown M, Bertulli R, Judson IR. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study. Journal of Clinical Oncology 2005; 23(24): 5795–5804.

  9. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR; EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. European Journal of Cancer 2005; 41(12): 1751–1757.
The GI CANCER Institute raises funds to support the Australasian Gastro Inestinal Trials Group (AGITG).